Find disease awareness content and relevant supporting materials
FDA approves Recorlev for Cushing’s syndrome.- Xeris Biopharma
Xeris Biopharma announced the FDA approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.
European Commission approval for Isturisa for the treatment of people with endogenous Cushing’s syndrome.- Recordati
Recodati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that purpose.